{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "CHF", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.011, "exchange": "EBS", "shortName": "KINARUS N", "longName": "Kinarus Therapeutics Holding AG", "messageBoardId": "finmb_549194384", "exchangeTimezoneName": "Europe/Zurich", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "ch_market", "marketState": "REGULAR", "esgPopulated": false, "sharesOutstanding": 1069529984, "fiftyDayAverage": 0.011792, "fiftyDayAverageChange": -0.00079200044, "fiftyDayAverageChangePercent": -0.06716421, "twoHundredDayAverage": 0.015796, "twoHundredDayAverageChange": -0.004796, "twoHundredDayAverageChangePercent": -0.30362117, "marketCap": 11764830, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1656486000000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683877478, "regularMarketDayHigh": 0.011, "regularMarketDayRange": "0.011 - 0.011", "regularMarketDayLow": 0.011, "regularMarketVolume": 352225, "regularMarketPreviousClose": 0.011, "bid": 0.0102, "ask": 0.011, "fullExchangeName": "Swiss", "regularMarketOpen": 0.011, "averageDailyVolume3Month": 1328336, "averageDailyVolume10Day": 361507, "fiftyTwoWeekLowChange": 0.0028, "fiftyTwoWeekLowChangePercent": 0.3414634, "fiftyTwoWeekRange": "0.0082 - 0.0366", "fiftyTwoWeekHighChange": -0.025600001, "fiftyTwoWeekHighChangePercent": -0.6994536, "fiftyTwoWeekLow": 0.0082, "fiftyTwoWeekHigh": 0.0366, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "KNRS.SW"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Technologiepark Basel", "address2": "Hochbergerstrasse 60C", "city": "Basel", "zip": "4057", "country": "Switzerland", "phone": "41 61 633 29 71", "website": "https://www.kinarus.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.", "companyOfficers": [], "maxAge": 86400}}], "error": null}}